Global Afutuzumab Market Research Report 2024
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Afutuzumab Market Research Report 2024
Afutuzumab, more commonly known as obinutuzumab is a humanized type II monoclonal antibody against CD20 (coded for by MS4A1 for the treatment of Chronic lymphocytic leukemia, CLL. It may have more direct antibody-dependent cell-mediated cytotoxicity and possibly more direct cytotoxicity than previously available type I antibodies such as rituximab and ofatumumab which have more complement-dependent cytotoxicity.
According to Mr Accuracy reports’s new survey, global Afutuzumab market is projected to reach US$ million in 2034, increasing from US$ million in 2024, with the CAGR of % during the period of 2023 to 2034. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Afutuzumab market research.
Key manufacturers engaged in the Afutuzumab industry include BOC Sciences, Carbosynth, Roche Group, TargetMol Chemicals, Wonda Science, Absin Bioscience, Chunchuang (Wuhan) Technology, Hubei Kele Fine Chemical and Jiangxi Ruiweier Biotechnology, etc. Among those manufacturers, the top 3 players guaranteed % supply worldwide in 2024.
When refers to consumption region, % volume of Afutuzumab were sold to North America, Europe and Asia Pacific in 2024. Moreover, China, plays a key role in the whole Afutuzumab market and estimated to attract more attentions from industry insiders and investors.
Report Scope
This report, based on historical analysis (2018-2024) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Afutuzumab market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
BOC Sciences
Carbosynth
Roche Group
TargetMol Chemicals
Wonda Science
Absin Bioscience
Chunchuang (Wuhan) Technology
Hubei Kele Fine Chemical
Jiangxi Ruiweier Biotechnology
Qingdao Jieshikang Biotechnology
Shanghai Biochempartner
Shanghai Macklin Biochemical
Shanghai Qiming Biotechnology
Shanghai Saimai Biotechnology
Shanghai Shize Biological Technology
Shanghai Yifei Biotechnology
Shanghai Yu'ang Chemical
Tianmen Hengchang Chemical
Wuhan Sunrise Technology Development
Wuhan Yingnuo Pharmaceutical Technology
Segment by Type
Patent
Generic
Chronic Lymphocytic Leukemia
Follicular Lymphoma
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Afutuzumab report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source
According to Mr Accuracy reports’s new survey, global Afutuzumab market is projected to reach US$ million in 2034, increasing from US$ million in 2024, with the CAGR of % during the period of 2023 to 2034. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Afutuzumab market research.
Key manufacturers engaged in the Afutuzumab industry include BOC Sciences, Carbosynth, Roche Group, TargetMol Chemicals, Wonda Science, Absin Bioscience, Chunchuang (Wuhan) Technology, Hubei Kele Fine Chemical and Jiangxi Ruiweier Biotechnology, etc. Among those manufacturers, the top 3 players guaranteed % supply worldwide in 2024.
When refers to consumption region, % volume of Afutuzumab were sold to North America, Europe and Asia Pacific in 2024. Moreover, China, plays a key role in the whole Afutuzumab market and estimated to attract more attentions from industry insiders and investors.
Report Scope
This report, based on historical analysis (2018-2024) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Afutuzumab market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
BOC Sciences
Carbosynth
Roche Group
TargetMol Chemicals
Wonda Science
Absin Bioscience
Chunchuang (Wuhan) Technology
Hubei Kele Fine Chemical
Jiangxi Ruiweier Biotechnology
Qingdao Jieshikang Biotechnology
Shanghai Biochempartner
Shanghai Macklin Biochemical
Shanghai Qiming Biotechnology
Shanghai Saimai Biotechnology
Shanghai Shize Biological Technology
Shanghai Yifei Biotechnology
Shanghai Yu'ang Chemical
Tianmen Hengchang Chemical
Wuhan Sunrise Technology Development
Wuhan Yingnuo Pharmaceutical Technology
Segment by Type
Patent
Generic
Segment by Application
Chronic Lymphocytic Leukemia
Follicular Lymphoma
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Afutuzumab report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source